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The absence of effective therapeutics against Alzheimer’s disease (AD) is a result of the
limited understanding of its multifaceted aetiology. Because of the lack of chemical tools
to identify pathological factors, investigations into AD pathogenesis have also been
insubstantial. Here we report chemical regulators that demonstrate distinct speciﬁcity
towards targets linked to AD pathology, including metals, amyloid-b (Ab), metal–Ab, reactive
oxygen species, and free organic radicals. We obtained these chemical regulators through a
rational structure-mechanism-based design strategy. We performed structural variations of
small molecules for ﬁne-tuning their electronic properties, such as ionization potentials and
mechanistic pathways for reactivity towards different targets. We established in vitro and/or
in vivo efﬁcacies of the regulators for modulating their targets’ reactivities, ameliorating
toxicity, reducing amyloid pathology, and improving cognitive deﬁcits. Our chemical tools
show promise for deciphering AD pathogenesis and discovering effective drugs.
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M
ultifactorial disease pathology is a unifying theme
of Alzheimer’s disease (AD), the most common of
all neurodegenerative diseases1–3. Misfolded protein
aggregate formation, metal ion dyshomeostasis and oxidative
stress are some of the many factors that have been implicated
in AD onset and progression1–13. The inter-relationships
between these individual facets further impede our ability
to fully comprehend the disease mechanisms and thus identify
the most upstream causative elements. For example, the
production of metal–protein complexes can subsequently
promote the misfolding and stabilization of abnormal and toxic
protein conformations, along with the generation of reactive
oxygen species (ROS) through Fenton-like chemistry (in the case
of redox-active metals)1–3,6–11,13–19. Thus, to address the
inherent complexities of AD, novel strategies must be available
for determination of pathological factors (for example, misfolded
proteins, metal ions and ROS) and elucidation of their individual
or inter-related roles in the disease.
The rational design of chemical tools to speciﬁcally probe
individual pathological facets of interest and modulate their
activities in vitro is valuable for providing a molecular-level
understanding of AD pathogenesis. Such molecular-level ﬁndings
cannot be easily achieved from other commonly used in vivo
or genetic approaches that are further limited by the absence of
model systems that completely mimic human AD2,3,20–25.
Particularly, chemical tools with the ability to speciﬁcally
interact with different targets of interest must be devised. To
date, the development of tools to investigate the involvement of
metal-free Ab, metal–Ab and ROS in AD pathology has been
impaired due to a few key reasons. First, there have been a limited
number of suitable molecular frameworks that can be used as a
starting point for rational structure-based design and possess the
biological properties required (for example, blood–brain barrier
(BBB) permeability, water solubility)2,20–26. Furthermore, there is
little understanding of how slight structural alterations to existing
Ab-imaging frameworks vary tools’ reactivity and target
speciﬁcity. Without such knowledge that could eventually be
applied to establish the criteria for newly designed tools,
researchers must rely on costly, time-consuming high-
throughput screening methods to discover effective molecules.
Finally, there are limited reports that describe the modes of action
between chemical tools and targets of interest at the molecular
level22,24,25,27–29. Correct applications of chemical tools cannot
be pursued without detailed information on how the molecule
and protein interact.
Herein, we report chemical tools (particularly, chemical
regulators) designed based on a structure-mechanism-based
concept. This design principle exempliﬁes that different
properties (for example, metal binding, Ab interaction and
ionization potentials (IPs)) of small molecules afford chemical
tools that have speciﬁc reactivity with distinct pathological targets
associated with AD (that is, metals, metal-free and metal-bound
Ab, ROS and free organic radicals; Fig. 1a) through
disparate mechanistic pathways. Such chemical regulators were
readily obtained through slight structural variations to a parent
framework (Fig. 1a). On the basis of biochemical, biophysical and
computational approaches, our chemical regulators are indicated
to modulate metal-free or metal-bound Ab aggregation in vitro to
different degrees through multiple structure-dependent
mechanisms (for example, complex or covalent adduct formation
with peptides and peptide modiﬁcations). In addition, structural
modiﬁcations to the framework are presented to tune regulatory
activities towards ROS and free organic radicals, as predicted by
their IPs. Furthermore, the in vivo efﬁcacy for our chemical
regulator (1, Fig. 1a) was conﬁrmed in an AD mouse model.
Overall, our studies demonstrate the structure-mechanism-based
development of chemical tools capable of targeting and control-
ling individual or inter-related AD pathological factors via minor
structural modiﬁcations to a parent entity.
Results
Rational design and characterization of small molecules. Four
small molecules (1–4; Fig. 1a) with similar chemical structures
were rationally designed to interact with and regulate
distinct targets (that is, metals, metal-free Ab, metal (Cu(II) or
Zn(II))–Ab, ROS, free organic radicals; Fig. 1a) by incorporating
structural moieties for metal binding and Ab interaction into a
framework, along with potential antioxidant activity and BBB
permeability. These compounds were obtained and used after
puriﬁcation (Supplementary Methods). For metal chelation, the
molecules have two nitrogen (N) donor atoms provided by
structural portions of 2-picolylamine (for 1 and 2), quinolin-2-
ylmethanamine (for 3), or (1H-pyrrol-2-yl)methylamine (for 4)
(Fig. 1a). Moreover, for different Ab interacting properties, the
structures were varied by installing amino (for 1), 3,5-dimethoxy
(for 2), or dimethylamino (for 3 and 4) functionalities (Fig. 1a).
Furthermore, tuning the electronic properties, such as IPs, was
considered in our molecule design for their antioxidant activity.
The ﬁrst and second adiabatic IPs (IP1 and IP2) for 1–4 were
calculated in both the gas and aqueous phases (Fig. 1b-d).
These studies present that 2, relative to 1, 3 and 4, has higher IPs.
This is because the unpaired electron in the cation radical species
is computed to be mainly stabilized via p-delocalization on the
benzene ring, s-conjugation on the para-substituted position, and
combinations of p-delocalization and s-conjugation features.
As shown in Fig. 1c, the singly occupied molecular orbitals
(SOMOs) of the cationic radicals of 1, 3 and 4 are located on
the benzene ring and the para-diamino substitution
(via p-delocalization and s-conjugation), whereas the radical on
2 is mainly located at the benzene ring. In addition, the
para-substituted groups of 1, 3 and 4 can be mixed into the
SOMOs, but meta-substitutions in 2 cannot. As a result, the
amino group in 1, 3 or 4 raises the level of SOMOs by its
mesomeric effect, in contrast to the methoxy groups in 2 lowering
the SOMOs by the inductive effect. Thus, 2 is least likely to
undergo oxidation. Lastly, the BBB permeability of 1–4 was
examined. First, adherence to Lipinski’s rules and calculated
logBB values were conﬁrmed. All calculated values suggest that 1–
4 could penetrate the BBB, along with the experimental results
(permeability values, –logPe) from an in vitro parallel artiﬁcial
membrane permeability assay adapted for the BBB
(Supplementary Table 1).
Modulation of metal-free and metal-induced Ab aggregation.
The ability of 1–4 to control the aggregation of both metal-free
Ab and metal-Ab in inhibition (Fig. 2) and disaggregation
experiments (Supplementary Fig. 1) was evaluated using the two
major Ab isoforms (Ab40/Ab42)1–3,6,16 found in the AD-affected
brain. Molecular weight (MW) distributions and morphologies of
the resulting Ab species were determined by gel electrophoresis
followed by western blotting (gel/western blot) and transmission
electron microscopy (TEM). Generally, under the experimental
conditions employed herein, compound-free Ab samples
with and without metal ions assemble into a distribution of
large aggregates that are too big to penetrate into the gel matrix,
which yields very little smearing in the gel/western blots, but they
can be visualized by TEM. The administration of compounds,
able to interact with Ab, inhibit the formation of high MW
aggregates, and/or disassemble preformed aggregates, typically
generates smaller-sized Ab species that can enter into the gel and
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produce a substantial amount of streaking compared with the
samples containing Ab only.
The alteration of metal-free Ab aggregation by 1–4 was ﬁrst
studied. Noticeable inﬂuence of 1–3 on metal-free Ab aggregation
was not observed (Fig. 2b–d, Supplementary Figs 1 and 2).
Changing the pyridine (from 1 and 2) and quinoline (from 3)
moieties to a pyrrole (from 4), however, had a pronounced
inﬂuence on metal-free Ab aggregation. Treatment of Ab40 with 4
produced aggregates that were 450 kDa in both inhibition and
disaggregation samples, while increased species (MWr50 kDa)
were detected in the case of Ab42 by gel/western blots, which was
more evident in experiments of inhibition over disaggregation
(Fig. 2c and Supplementary Fig. 1b,d). Additionally, in the
inhibition and disaggregation experiments using Ab40, smaller
and more amorphous species were indicated by TEM (Fig. 2d
and Supplementary Fig. 1c); however, these changes were less
noticeable in the samples containing Ab42 (Supplementary Figs 1e
and 2).
Next, Cu(II)- and Zn(II)-induced aggregation was detected
upon treatment of 1–4. 1 demonstrated a capacity to only redirect
Cu(II)-promoted Ab40 and Ab42 aggregation (Fig. 2c and
Supplementary Fig. 1b,d). TEM revealed the presence of less
structured forms of aggregates (Fig. 2d and Supplementary
Figs 1c,e and 2). 1 did not show any noticeable activity towards
Zn(II)-mediated Ab40/Ab42 aggregation even at higher Zn(II)
concentrations (Fig. 2f). Compound 2 was found to only have
a modulating activity at higher Cu(II) concentrations, indicated
by gel/western blot and TEM (Fig. 2c–e and Supplementary
Figs 1b–e and 2).
The Cu(II)-speciﬁc activity of 1 and 2 is contrasted to 3 which
modulates Ab aggregation involved by both Cu(II) and Zn(II)
(Fig. 2c,d and Supplementary Fig. 1b–e). 4 was also found in
the gel/western blots to redirect both Cu(II)- and Zn(II)-induced
Ab aggregation, indicating the production of smaller less
structured ﬁbrils, which was visualized by TEM (Fig. 2c,d and
Supplementary Figs 1b–e and 2). Overall, the results from
gel/western blots and TEM demonstrate that by varying the
structures of compounds we are able to change their potential to
interact with metal-free Ab and/or metal–Ab (both Cu(II)–Ab
and Zn(II)–Ab; only Cu(II)–Ab) and divert the aggregation
pathways to form potentially nontoxic off-pathway species27–29.
Mediation of oxidative stress. The capability of 1–4 to scavenge
free organic radicals was explored in cell lysates using the
Trolox equivalence antioxidant capacity (TEAC) assay used
for testing their aptness to quench the cationic organic radical
of 2,20-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)
compared with the known antioxidant, Trolox, a water-soluble
analogue of vitamin E25,28,29. All compounds showed a greater
free radical scavenging ability than Trolox (Fig. 3a). Speciﬁcally,
1, 3 and 4 containing the p-amine substitutions had a greater
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Figure 1 | Targets associated with AD and ionization potentials of chemical tools (1–4). (a) Structures of 1–4 [1, N1-(pyridin-2-ylmethyl)benzene-
1,4-diamine; 2, 3,5-dimethoxy-N-(pyridin-2-ylmethyl)aniline; 3, N1,N1-dimethyl-N4-(quinolin-2-ylmethyl)benzene-1,4-diamine; 4, N1-((1H-pyrrol-2-
yl)methyl)-N4,N4-dimethylbenzene-1,4-diamine] and their targets (metal-free Ab, Cu(II)–Ab, Zn(II)–Ab and ROS). (b) Scheme of the oxidation of
p-phenylenediamines. (c) Isosurface plot of SOMOs of cationic radicals of 1–4 with an isovalue of 0.02 au (red: O; blue: N; grey: C; white: H).
(d) Calculated ionization potentials for 1–4 for the ﬁrst and second processes depicted in b in both the gas and aqueous phases.
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capacity than 2 with the 3,5-dimethoxy substitution. This
suggests that an electron donating p-amine functionality on the
backbone of molecules can increase their ability to be oxidized
and act as an antioxidant, consistent with calculated IP values
(Fig. 1b–d, vide supra).
Moreover, the inhibitory activity of 1–4 towards the generation
of hydroxyl radicals by Cu(I/II) through Fenton-like
reactions was evaluated using the 2-deoxyribose assay30. 1–3
could reduce the generation of hydroxyl radicals by
approximately half (Fig. 3b; note that 4 was not tested due to
poor solubility under the assay conditions). Together, our
frameworks with different aniline groups are shown to diminish
the presence and production of ROS, which could reduce
oxidative stress.
Regulation of metal-free and metal-treated Ab cytotoxicity.
The toxicity of compounds and their ability to alleviate
metal-free/-bound Ab toxicity were analysed employing human
neuroblastoma SK-N-BE(2)-M17 (M17) cells. 1 and 2 were
indicated to be nontoxic in the M17 cells with and without Cu(II)
and Zn(II) at the tested concentrations (up to 20mM) that did not
show interference with the analysis window of the cell viability
assay (Fig. 3c and Supplementary Fig. 3). 3 and 4, however,
decreased cell viability in the presence of Cu(II) (B70–80%
viability at 20 mM of compounds) for 24 h as well as in the
absence of Cu(II) for 48 and 72 h (up to B60% viability). In
addition, when 1 or 2 was co-incubated with Ab40/Ab42 in the
absence and presence of Cu(II) and Zn(II), the toxicity induced
by metal–Ab was diminished (Fig. 3d,e). Note that 3 and 4 were
not studied with Ab species due to its noticeable toxicity with
Cu(II) in the absence of peptides. These results may stem from
redirection of the aggregation pathways of Ab40 and Ab42 to
produce off-pathway species as observed in the gel/western
blot and TEM studies that are less toxic than on-pathway Ab
aggregates27–29, along with their capability of modulating
oxidative stress (vide supra).
In vivo efﬁcacy. The in vivo efﬁcacy of 1 was evaluated using the
5FAD AD mouse model due to its speciﬁcity for mediating
Cu(II)–Ab aggregation and toxicity in vitro and in living
cells, along with its solubility in aqueous media (the HCl
salt of 1, B800mgml 1 in water) and regulatory activity
towards oxidative stress (vide supra). We refrained from
analysing 2 in vivo because it possessed the same target speciﬁcity
as 1 (that is, speciﬁcity for Cu(II)–Ab), but it requires
elevated concentrations of Cu(II) and had much lower degrees
of water solubility and antioxidant activity relative to 1. 3
and 4 were also not selected for in vivo analysis due to their lower
cell viability (with respect to 1) with and without Cu(II) (vide
supra).
1 was administered to the 3-month-old 5FAD mice at a daily
dosage of 1mg kg 1 by an intraperitoneal injection every day for
30 days. All mice tolerated the repeated treatments and
experienced no gross changes in the post-necropsy evaluation.
There was no difference in body weight between 1- and
vehicle-treated 5FAD mice throughout the drug administration
period (Supplementary Table 2). Daily repeated administrations
of 1 signiﬁcantly lessened the amyloid pathology in the brains of
5FAD mice. The total Ab level, composed of phosphate buffered
saline (PBS)-, SDS- and formic acid (FA)-soluble Ab40/Ab42,
became signiﬁcantly lower than that in the vehicle-treated 5FAD
mice (Fig. 4a(ii)). Amounts of Ab oligomers and aggregates also
decreased in the 1-treated 5FAD mice (Fig. 4a(i,ii)). In addition,
1 reduced the loads of Ab deposits in the brain, as determined by
the evaluation of the 4G8-immunoreactive or congophilic Ab
plaques (Fig. 4a(iii)).
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Moreover, the Morris water maze test was conducted
to evaluate the cognitive functions of 5FAD mice in response
to the persistent treatment with 1. During the trial trainings,
the 1-treated 5FAD mice could ﬁnd the hidden escape platform
faster than the vehicle-treated 5FAD mice, which was compar-
able to the performance of wild-type mice at the same age
(Fig. 4b(i)). The probe trials also showed signiﬁcant improvement
of the long-term spatial memory in the 1-treated animals
(Fig. 4b(ii,iii)). Therefore, 1 could produce beneﬁcial effects to
prevent or reverse cognitive deﬁcits as well as amyloid pathology
in 5FAD mice. The alleviation of AD symptoms and pathology,
which arises from mediating Cu(II)–Ab aggregation and toxicity
by treatment with 1, is suggested to be effective
as indicated by the previously reported studies using
copper ionophores (for example, clioquinol and PBT2) in
transgenic AD mice31,32.
Characterization of solution species. Studies of the species
present in solution indicated that 1 and 2 were stable over 5 h
(Supplementary Fig. 4a–h). 3 showed changes in its
Ultraviolet-Visible (UV-vis) spectra after 5 h of incubation
occurring at a very slow rate (Supplementary Fig. 4i and
Supplementary Table 3). Electrospray ionization mass
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spectrometry (ESI–MS) studies, however, exhibited no change in
the major peak at 278 m/z corresponding to the [MþH]þ ion
after 5 h of incubation supporting the stability of 3
(Supplementary Fig. 4j–l). Moreover, 4 was unstable with a half-
life ofB40min (Supplementary Table 3). After 5 h of incubation,
ESI–MS identiﬁed a peak at 137 m/z corresponding to [M þ
H]þ of N,N-dimethyl-p-phenylenediamine (DMPD)29 but other
possible degradation products of 4 could not be identiﬁed
(Supplementary Fig. 4m–p). This could be due to the reported
propensity of the pyrrole moiety to polymerize as possibly
evidenced by unidentiﬁed peaks at 288 and 297 m/z
(Supplementary Fig. 4o)33,34. DMPD was recently reported to
interact with both metal-free Ab and metal–Ab and redirect their
self-assembly routes to form off-pathway aggregates, suggested to
be less toxic29.
The stability in the presence of Cu(II) was also determined. UV-
vis and ESI–MS studies indicated that 1 initially formed CuL2
complexes (L¼ ligand; [M þ H]þ ¼ 460 m/z), with the half-life
beingB5min, followed by the generation of one-electron ([M]þ )
or two-electron oxidation ([M þ H]þ ) products at 198 m/z
(Supplementary Fig. 5a–d and Supplementary Table 3). These
types of oxidation products are well deﬁned in the literature for
unsubstituted and substituted p-phenylenediamine derivatives with
an oxidant35–38. 3 also presented UV-vis spectral changes similar
to 1 with the decay of the peak attributed to Cu(II) binding at
B450 nm (half-life B50min) corresponding to the growth of a
new peak at B550 nm comparable to the reported one-electron
oxidation products of p-phenylenediamine derivatives
(Supplementary Fig. 5i). ESI–MS studies conﬁrmed the initial
formation of a CuL2 complex of 3 which was observed to degrade
into the metal-free two-electron oxidized form (Supplementary
Fig. 5j–l). Note that other species were detected by ESI–MS after
5 h of incubation, possibly from further degradation of 3. The
identity of these species will be the subject of future studies.
In the case of 2, the addition of Cu(II) created a new peak at
B375 nm that did not dissipate over 5 h (Supplementary Fig. 5e).
ESI–MS identiﬁed an ion at 588 m/z corresponding to the CuL2
complex ([M þ K]þ ; Supplementary Fig. 5f-h). Different
from 1 and 3, 2 generated a complex with Cu(II) without any
further transformations over the course of 5 h; thus, the binding
afﬁnity of 2 for Cu(II) was estimated using UV–vis variable-pH
titrations. The presence of a 1:1 complex was observed with an
approximate disassociation constant in the micromolar range
(Supplementary Fig. 6). This low binding afﬁnity is likely to be
too weak to interact with the low micromolar to high picomolar
(B10 7–10 11M)1,16,39 binding afﬁnity for the ﬁrst Cu(II)
binding site of Ab. Interaction is possible, however, with the
second metal binding site in Ab which has a weaker afﬁnity of
B10 5M for Cu(II)1,16,39. This is consistent with the results
from the gel/western blots where at least two equivalents of Cu(II)
are required for activity (Fig. 2e), suggesting that 2 can only
interact with Ab when both metal binding sites are metalated
(vide supra).
Lastly, the addition of Cu(II) to 4 resulted in intense double peaks
at B510 and 550nm within 1min, similar to the previously
reported spectra of the cationic radical of DMPD (Supplementary
Fig. 5m)29. ESI–MS displayed the peaks at 137 and 216 m/z
corresponding to [DMPDþH]þ and [4þH]þ , respectively
(Supplementary Fig. 5n,o; note that longer incubations led to
precipitation thus limiting analysis). This suggests that DMPD may
be responsible for the activity of 4 towards Ab (ref. 29).
Mass spectrometric studies for Ab and metal–Ab interactions.
To investigate the interactions between Ab and 1–4, nano-elec-
trospray ionization MS (nESI-MS) combined with ion mobility–
mass spectrometry (IM–MS), optimized for the detection of non-
covalent protein complexes40–42, was employed. Data obtained
from the samples incubated for 30min indicated that 1–3
exhibited a metal-dependent interaction with both Ab40 and Ab42
(Fig. 5 and Supplementary Fig. 7, respectively). Both 1 and 3 were
capable of producing Cu–ligand-dependent signals corresponding
to a mass 89Da lighter than the apo Ab40/Ab42, albeit with clear
differences in the abundance of this product. Tandem mass
spectrometry (MS2) sequencing of the Ab peak supported that it
corresponded to a N-terminally truncated form of the peptide
(Supplementary Fig. 8 and Supplementary Table 5), consistent
with data previously reported for L2-b (ref. 25). No data acquired
presented a stable interaction between 1 and 3 with either Ab40 or
Ab42 under our conditions, indicative of the formation of a
transient Cu-containing ternary complex.
2 produced stable ternary complexes comprising single
equivalents of both Ab40/Ab42 and the ligand, with one or two
Cu(II) bound. IM–MS data support that binding of 2 to Ab40 shifts
the arrival time distributions when compared with the ligand-free
complexes (Fig. 5b,c and Supplementary Fig. 7). Because of the
increased chemical noise, we were unable to produce IM–MS
observations for these compounds in the presence of Ab42. Using
the Ab40 as a model system which exhibited reduced chemical
noise and kinetics of aggregation, these results demonstrate that
the formation of a ternary complex between Cu(II), Ab and 2
results in an altered downstream Ab aggregation pathway. This is
consistent with previous observations for other small molecules
that can modulate metal–Ab reactivity25,27. In the absence of
Cu(II), the above small molecules were not observed in complex
with the peptide (Supplementary Fig. 9).
In addition, the Cu(II)–Ab40/Ab42 samples prepared under the
conditions of the inhibition experiments shown in Fig. 2
(for example, buffer, 24 h incubation) were analysed by
matrix-assisted laser desorption ionization mass spectrometry
(MALDI–MS). As depicted in Supplementary Fig. 10, ions
smaller than full-length Ab40 (loss of 89Da) appeared from the
samples treated with 1 and 3, consistent with the nESI-MS results
(vide supra; Fig. 5a). Along with truncation of the peptide, upon
incubation of Cu(II)–Ab with 1 or 3 for 24 h, oxidation of Ab40
was also observed. As indicated by nESI-MS and IM–MS data, Ab
added with 2 was not indicated to be modiﬁed even after 24 h
(Supplementary Fig. 10). Thus, both events (that is, truncation
and oxidation of Ab) by 1 and 3 with Cu(II) being present might
be responsible for redirecting Ab aggregation pathways.
To determine if intact or transformed 4 would be the active
species which could interact with Ab, both copper-free and
copper-present samples incubated with the molecule were also
monitored. When 4 was reacted with metal-free Ab40 for 6 h
([Ab40]:[4]¼ 1:5, [Ab40]¼ 100mM), the compound, observed by
ESI–MS, was indicated to be degraded showing its multiple
fragments and their nonspeciﬁc adducts of monomeric and
oligomeric Ab species (Supplementary Fig. 11). Note that in
conditions comparable to the nESI-MS studies of 1–3 (Fig. 5), 4
was not shown to bind to Ab40 in 30min and 24 h long
incubations at 37 C (Fig. 5a and Supplementary Fig. 12). In the
case of the Ab samples incubated with 4 and Cu(II) for 1 h,
oxidized Ab was shown, along with formation of covalent
complexes of BQ29, Ab and/or Cu(II) (Fig. 5d). The generation of
oxidized Ab was also indicated in the sample incubated with Ab,
Cu(II) and 4 for 24 h under the same condition of the studies
(Fig. 2), analysed by MALDI–MS (Supplementary Fig. 10).
To identify the oxidation sites in Ab, MS2 analysis was
carried out on the non-oxidized and singly oxidized Ab40
(Supplementary Fig. 13). In the MS2 of the singly oxidized Ab,
ions larger than b35 fragments, including the ﬁrst 35 amino acid
residues from the N-terminus, existed as the oxidized form;
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however, both non-oxidized and oxidized forms were found in
fragments smaller than b34. These results suggest that oxidation
can occur at several sites, including the methionine residue (M35;
Ab sequence shown in Fig. 2a). As presented in Supplementary
Fig. 13, the smallest oxidized ion is b13 and no oxidation was
observed in the b9 fragment. Thus, along with M35 (ref. 43), H13
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and H14 could be additional plausible oxidation sites in Ab, as
previously reported44,45.
Together, our overall MS studies suggest that 1–4 can interact
with metal-free Ab and/or Cu(II)-bound Ab in different
manners. The distinct redirecting activity of 1–4 towards metal-
free and metal-treated Ab aggregation pathways, indicated in
both inhibition and disaggregation experiments (vide supra),
could be directed by multiple mechanisms, including Ab
modiﬁcations (that is, degradation and oxidation), non-covalent
complex formation, and covalently linked adduct generation. The
overall proposed mechanisms of 1–4 towards individual targets
are described in detail in the following sections (vide infra).
Computational studies for prediction of hydrolysis. Along with
calculations of IP1 and IP2 values (Fig. 1b–d, vide supra), to
further elucidate the modes of action of 1–4 towards Ab in the
presence of Cu(II), density functional theory calculations were
employed (Fig. 6a–d). A simpliﬁed model calculation on the SN2-
type cleavage of the C–N bond showed that 4 had the lowest
barrier for hydrolysis resulting in the production of DMPD
(Fig. 6c,d). This is consistent with the UV–vis and MS studies
(vide supra). Thus, 4 possibly reacts with both metal-free Ab and
metal–Ab, as indicated by DMPD29.
Proposed mechanisms for reactivities of 1–4 with targets.
Collecting the overall results from our optical, ESI–MS/IM–MS/
MALDI–MS, and computational investigations, we propose the
multiple modes of action of 1–4 towards targets. First, the modes
of action of our compounds to mediate the aggregation of
metal-free Ab and metal-Ab are suggested (Fig. 6e). Studies
presented herein indicate that the mode of action of 1 and 3 could
involve the formation of a transient ternary complex between Ab,
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Cu(II) and compound. This could be subsequently followed by
the oxidation of 1 and 3 as well as the oxidation and/or
degradation of the peptide by well-documented radical pathways
(proposed pathway A: radical-mediated peptide modiﬁcations;
Fig. 6e)43–48. 2 is most likely to undergo a different pathway of
Ab aggregation modulation due to its higher IPs (Fig. 1d).
Thus, it is proposed that the interaction of 2 with Cu(II)–Ab
results in the formation of a stable ternary complex consisting
of Ab, Cu(II) and 2 which subsequently diverts Cu(II)–Ab
aggregation pathways producing off-pathway species with
different conformations (proposed pathway B; stable ternary
complex formation; Fig. 6e). In the case of 4, based on the density
functional theory calculations, along with the experimentally
observed Ab–DMPDtransformed adducts, this molecule might be
transformed to DMPD via oxidative and hydrolytic pathways29,
which could be responsible for interaction and reactivity with
both metal-free and metal-associated Ab through the proposed
modes of action C and D (oxidative/hydrolytic transformations,
peptide adduct formation and/or peptide oxidation; Fig. 6e).
In addition, 1–4 are able to mediate oxidative stress caused by
the presence of free organic radicals by acting as antioxidants to
donate an electron to quench the radials49. This is evidenced by
their activity towards the radicals roughly correlating with the
calculated IPs (Fig. 1d) which measure the ease of releasing an
electron. Furthermore, in the presence of Cu(I/II), 1–3 can
also inhibit ROS generation. This activity is possibly originated
by 1–3 binding to copper and preventing it being reduced to
form ROS (for example, hydroxyl radicals)49, along with
compounds’ antioxidant activity. The previously discussed
electronic properties (for example, IPs, Fig. 1d) of the
compounds could also compliment this activity. More detailed
investigations of the modes of action of 1–4 towards targets will
be the subject of future studies.
Discussion
To date, effective drugs against AD are not available since the
pathological factors and pathways of AD are still unclear. To
identify such pathological features associated with AD, chemical
tools with distinct speciﬁcity towards various individual or
associated targets are needed. Herein, we designed four small
molecules based on a structure-mechanism-based design strategy
for targeting and regulating distinct pathological factors
(for example, metal ions, metal-free Ab, metal–Ab, ROS, free
organic radicals) linked to AD pathology as chemical tools useful
for AD research. Our studies indicate that the desired chemical
properties of small molecules can be achieved for reactions with
pathological features simply through minor structural variations
to a parent framework. In addition, such property tuning of small
molecules is observed to successfully afford different modes of
action towards the targets. Furthermore, along with in vitro
characterizations at the molecular level, the validation of our
chemical tool in the 5FAD AD mouse model conﬁrms its utility
in investigating AD aetiology. Therefore, our ﬁndings of the small
molecules, able to probe distinct pathological facets via disparate
mechanisms, demonstrate the feasibility of applying a structure-
mechanism-based design concept to rationally construct chemical
tools capable of illuminating the roles of multiple individual
targets and their inter-relationships in AD pathogenesis. More-
over, such chemical tools will provide an unconventional avenue
for discovering effective diagnostics and therapeutics for AD.
Methods
Parallel artiﬁcial membrane permeability assay adapted for BBB (PAMPA-BBB).
PAMPA-BBB experiments were conducted using the PAMPA Explorer kit
(pION Inc., Billerica, MA, USA) using previously reported protocols24,28,29.
Compounds (25mM, 200ml) in pH 7.4 Prisma HT buffer (pION) were added to the
wells of a donor plate (number of replicates¼ 12). The polyvinylidene ﬂuoride
(PVDF, 0.45mM) ﬁlter membrane on the acceptor plate was coated with BBB-1 lipid
formulation (5ml, pION). The acceptor plate was placed on top of the donor plate.
Brain sink buffer (BSB, 200ml, pION) was added to each well of the acceptor plate
and was incubated for 4 h at ambient temperature without stirring. UV–vis spectra of
the solutions in the reference, acceptor, and donor plates were measured using a
microplate reader. The PAMPA Explorer software v. 3.5 (pION) was used to
calculate the logPe values for compounds. CNS±designations were assigned by
comparison with compounds that were identiﬁed in previous reports50–52.
Ab aggregation experiments. Before experiments, Ab40 or Ab42 was dissolved in
ammonium hydroxide (NH4OH; 1% v/v, aq). The resulting solution was
aliquoted, lyophilized overnight and stored at 80 C. A stock solution of
Ab was then prepared by dissolving lyophilized peptide in 1% NH4OH (10 ml) and
diluting with ddH2O. The concentration of the solution was determined by
measuring the absorbance of the solution at 280 nm (e¼ 1,450M–1 cm–1 for Ab40;
e¼ 1,490M–1 cm–1 for Ab42). The peptide stock solution was diluted to a ﬁnal
concentration of 25mM in Chelex-treated buffered solution containing HEPES
(20 mM; pH 6.6 for Cu(II) samples; pH 7.4 for metal-free and Zn(II) samples) and
NaCl (150 mM). For the inhibition studies, compounds (ﬁnal concentration 50 mM,
1% v/v dimethyl sulfoxide (DMSO)) were added to the sample of Ab (25 mM) in
the absence and presence of a metal chloride salt (CuCl2 or ZnCl2; 25, 50, 100 or
125 mM) followed by incubation at 37 C with constant agitation for 24 h. For the
disaggregation studies, Ab with and without a metal chloride salt was incubated for
24 h at 37 C with constant agitation to generate preformed Ab aggregates. The
resulting samples were then treated with compounds (50 mM) and incubated with
constant agitation for additional 24 h.
Gel electrophoresis and western blotting. The Ab samples from in vivo or
in vitro experiments were analysed by gel electrophoresis followed by western
blotting using an anti-Ab antibody (6E10)24,25,27–29. Samples (10 ml) were
separated on a 10–20% Tris-tricine gel (Invitrogen, Grand Island, NY, USA).
Following separation, the proteins were transferred onto nitrocellulose membranes
and blocked with bovine serum albumin (BSA, 3% w/v, Sigma-Aldrich, St Louis,
MO, USA) in Tris-buffered saline (TBS) containing 0.1% Tween-20 (TBS-T) for
2 h at room temperature or overnight at 4 C. The membranes were incubated with
an anti-Ab antibody (6E10, 1:2,000, Covance, Princeton, NJ, USA) in a solution of
2% BSA (w/v in TBS-T) for 4 h at room temperature or overnight at 4 C.
After washing with TBS-T (3 , 10min), a horseradish peroxidase-conjugated goat
anti-mouse secondary antibody (1:5,000 in 2% BSA w/v in TBS-T; Cayman
Chemical Company, Ann Arbor, MI, USA) was added for 1 h at room temperature.
The Thermo Scientiﬁc SuperSignal West Pico Chemiluminescent Substrate
(Thermo Scientiﬁc, Rockford, IL, USA), Biosesang ECL Plus kit (Biosesang,
Gyeonggi-do, Republic of Korea), or a homemade ECL kit53 was used to visualize
the results on a ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA, USA).
Transmission electron microscopy (TEM). Samples for TEM were prepared
according to a previously reported method using glow-discharged grids
(Formar/Carbon 300-mesh, Electron Microscopy Sciences, Hatﬁeld, PA,
USA)24,25,27–29. Images for each sample were taken on a JEOL JEM-2100
transmission electron microscope (UNIST Central Research Facilities, Ulsan
National Institute of Science and Technology, Ulsan, Republic of Korea).
Cell viability studies. The M17 cell line was purchased from the American Type
Culture Collection (ATCC, Manassas, VA, USA). The cell line was maintained in
media containing 50% minimum essential medium and 50% F12 (GIBCO, Grand
Island, NY, USA), supplemented with 10% fetal bovine serum (Sigma), 100Uml 1
penicillin, and 100mgml 1 streptomycin (GIBCO). The cells were grown and
maintained at 37 C in a humidiﬁed atmosphere with 5% CO2. The cell culture
used in this work did not indicate mycoplasma contamination. Cell viability upon
treatment of compounds was determined using the MTT assay (Sigma). M17 cells
were seeded in a 96-well plate (15,000 cells in 100ml per well). The cells were
treated with Ab (20 mM) with or without CuCl2 or ZnCl2 (20 mM), followed by the
addition of compounds (20 mM, 1% v/v ﬁnal DMSO concentration), and incubated
for 24 h. After incubation, 25 ml MTT (5mgml 1 in phosphate buffered saline
(PBS, pH 7.4, GIBCO) was added to each well and the plate was incubated for 4 h
at 37 C. Formazan produced by the cells was solubilized using an acidic solution of
N,N-dimethylformamide (DMF, 50%, v/v aq) and SDS (20%, w/v) overnight at
room temperature in the dark. The absorbance was measured at 600 nm using a
microplate reader. Cell viability was calculated relative to cells containing an
equivalent amount of DMSO.
TEAC assay. The assay employing M17 cell lysates was conducted following the
protocol of the antioxidant assay kit purchased from Cayman Chemical Company
(Ann Arbor, MI, USA) with minor modiﬁcations25,28,29. For the antioxidant assay
using cell lysates, cells were seeded in a six-well plate and grown to B80–90%
conﬂuence. Cell lysates were prepared following a previously reported method with
modiﬁcations54. M17 cells were washed once with cold PBS (pH 7.4, GIBCO) and
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harvested by gently pipetting off adherent cells with cold PBS. The cell pellet was
generated by centrifugation (2,000g for 10min at 4 C). This cell pellet was
sonicated on ice (5 s pulses, three times with 20 s intervals between each pulse) in
2ml of cold Assay Buffer (5mM potassium phosphate, pH 7.4, containing 0.9%
NaCl and 0.1% glucose). The cell lysates were centrifuged at 5,000g for 10min at
4 C. The supernatant was removed and stored on ice until use. For standard and
samples in 96-well plates, 10 ml of the supernatant of cell lysates was delivered
followed by addition of compound, metmyoglobin, ABTS and H2O2 in order.
After 5min incubation at room temperature on a shaker, absorbance values at
750 nm were recorded. The antioxidant concentration was calculated according to
the measured absorbance (% inhibition¼ 100 (A0 – A)/A0, where A0 is
absorbance of the supernatant of cell lysates). The measurements were conducted
in triplicate.
2-Deoxyribose assay. The ability of 1–3 to decrease free radical formation from
Fenton-like chemistry by Cu(I/II) was determined using previously reported
procedures28,30. To summarize, solutions of phosphate buffer (50mM NaH2PO4,
pH 7.2) treated with Chelex overnight, compound (125 mM in water),
CuCl2 (10 mM), 2-deoxy-D-ribose (15mM), H2O2 (200 mM), and sodium
ascorbate (2mM) were mixed in the listed order and incubated at 37 C
with constant agitation. These conditions were chosen to optimize the
formation of the chromogen produced during the course of the assay.
After 1 h, the samples were quenched with trichloroacetic acid (2.8% w/v, 200 ml)
and 2-thiobarbituric acid (1% w/v, 200 ml) and heated at 100 C for 20min.
The samples were allowed to cool for 5min before measuring the absorbance
values at 532 nm on a microplate reader. Samples without compounds were
also tested as a control. Normalized absorbance values were calculated as
previously reported28.
Determination of solution speciation for 2 and Cu(II)–2 complex. The
pKa value for 2 was determined by UV–vis variable-pH titrations as
previously reported24,55. To establish the pKa value, a solution (10mM NaOH, pH
12, 100mM NaCl) of 2 (100 mM) was titrated with small amounts of HCl. At least
30 spectra were recorded in the range of pH 2–10. Similarly, a solution containing
CuCl2 and 2 (50 mM) in a metal to ligand ratio of 1:2 was titrated with small
additions of HCl and at least 30 spectra were recorded over the range pH 2–7.
The acidity and stability constants were calculated by using the HypSpec program
(Protonic Software, UK)56. Speciation diagrams were modelled in the HySS2009
program (Protonic Software)57.
Stability studies. The stability of 1–4 (50mM) in the absence and presence
of CuCl2 (25 mM) was monitored every 10min using UV–vis for 5 h in buffer
(20 mM HEPES, pH 7.4, 150 mM NaCl; 1% DMSO) at 37 C. The resulting spectra
were corrected for baseline shifts at 800 nm and the half-life and rate of decay of
the absorbance at 250, 385 and 400 nm for 4, [Cu(II)þ 1], and [Cu(II)þ 3],
respectively, was calculated using the ﬁrst-order exponential decay function as
implemented in Origin 9.1 (OrginLab Corp., Northampton, MA, USA). Addi-
tionally, the species present were identiﬁed using ESI–MS. Samples containing
1–4 (50 mM) with or without CuCl2 (25 mM) were incubated in ddH2O (1%
DMSO) at 37 C for the selected time points before being freshly frozen using
liquid nitrogen and stored at 80 C until they were thawed immediately
before measurement.
Ion mobility–mass spectrometry (IM–MS). All IM–MS experiments were carried
out on a Synapt G2 (Waters, Milford, MA)27–29,58. Samples were ionized using a
nano-electrospray source operated in positive ion mode. MS instrumentation was
operated at a backing pressure of 2.7mbar and sample cone voltage of 40V.
The m/z scale was calibrated using 20mgml 1 aqueous cesium iodide. For
peptide-metal ligation studies, the aliquots of Ab peptides (ﬁnal concentration
18mM) were sonicated for 5 s before pre-incubation with or without a source of
Cu(II) (copper(II) acetate) at 37 C for 10min. After pre-incubation, the samples
were treated with or without 1–4 (ﬁnal concentration 160mM) and incubated at
37 C for 30min before analysis. Solution conditions were 100mM ammonium
acetate (pH 7.5) with 1% v/v DMSO. Covalent binding studies with 4 were
performed by incubating aliquots of Ab with the ligand at a ratio of 1:0, 1:5 and
1:25 in water for either 24 h or a week at 25 C. After incubation the samples were
lyophilized for storage until analysis. Immediately before analysis samples were
reconstituted to 50 mM peptide concentration in 1,1,1,3,3,3-hexaﬂuoro-2-propanol,
sonicated and diluted further to 25 mM for data acquisition. Accurate mass values
for ligand-bound complexes were calculated using the monoisotopic peak
difference between apo and ligated states with errors reported as a function of two
times the s.d. collision cross section (CCS) measurements were externally calibrated
using a database of known values in helium, using values for proteins that bracket
the likely CCS and ion mobility values of the unknown ions58,59. CCS values are the
average of six replicates with errors reported as the least square product. This least
square analysis combines inherent calibrant error from drift tube measurements
(3%)59. calibration curve error, and two times the replicate s.d. error. All other
conditions are consistent with previously published methods25.
Electrospray ionization mass spectrometry (ESI–MS). Ab (100 mM) was
incubated with 4 (500 mM) in 100mM ammonium acetate, pH 7.5, without and
with the addition of CuCl2 (100 mM) for 1 h at 37 C without agitation. Before
injection into the mass spectrometer, the resulting Ab was diluted by 10-fold.
ESI–MS analysis was performed using a Synapt G2-Si quadrupole time-of-ﬂight
mass spectrometer (Waters, Manchester, UK) equipped with electrospray
ionization source. The capillary voltage, sampling cone voltage, and source
temperature were set to 2.8 kV, 70V, and 60 C, respectively. The backing pressure
was adjusted to 3.2mbar.
Matrix-assisted laser desorption ionization mass spectrometry (MALDI–MS).
Ab samples (prepared in the same procedure with Ab aggregation experiments)
were mixed with the equivalent volume of the matrix solution and loaded on the
target plate. The matrix solution was prepared with a-cyano-4-hydroxycinnamic
acid (Sigma-Aldrich) by dissolving in 40% CH3CN and 2% triﬂuoroacetic acid and
adjusting the concentration to 5mgml 1. MALDI–MS analysis was conducted
using an Ultraﬂex III time-of-ﬂight mass spectrometer (Bruker Daltonics, Bremen,
Germany). Mass spectra were acquired over the range of 1,000–6,000 m/z.
Calculation of transition state energies and ionization potentials. First-
principles calculations using Gaussian09 (ref. 60) were carried out for 1–4 in order
to study the SN2 hydrolysis and their one and two-electron oxidation. For the direct
C–N bond hydrolysis mechanism assisted by Cu(II), ﬁve additional water mole-
cules were added to the ﬁrst hydration sphere of Cu(II) in addition to the water
molecule acting as a nucleophile. The structure optimizations were performed in
the vacuum at M06/6-31G(d) level. The Los Alamos effective-core potential (ECP)
LanL2DZ basis set was applied for Cu(II). The hydration effect was taken into
account by additional single point calculations with polarizable continuum model
at M06/6-31G(d) level. To ﬁnd transition states as the ﬁrst-order saddle points on
the PES, Berny algorithm was used. The validity of the transition states were
conﬁrmed by frequency calculations (one imaginary) corresponding to the trans-
lational motion of the carbon from C–N bond. For the two-electron oxidation of 1–
4, we calculated two successive adiabatic ionization potentials accounting for the
sequential loss of electrons. The radical cation from the ﬁrst ionization is assumed
to undergo immediate deprotonation before the second ionization. All the relevant
chemical species were optimized at M06/6-31G(d) level, and their thermodynamic
parameters were calculated at M06/6-311þG(2df,2p) level. Inclusion of the sol-
vation effect of water using the polarizable continuum model reduces the ionization
potential, but the overall trend is conserved.
Animal studies. The amyloidogenic characteristics of 5FAD mice have been
described previously29. In brief, 5FAD mice express the Swedish/London/Florida
mutations of the human amyloid precursor protein (hAPP) and the M146L/L286V
mutations of the human presenilin-1 (PSEN1). They develop the early and robust
pathology of AD with the cognitive and behavioural impairments. The 5FAD mice
have been widely used to test the possible efﬁcacy of a compound targeted for AD25,29.
We maintained the mice on a C57BL/6 SJL hybrid background. All animal
experiments were performed in accordance with the guidelines of the Asan Institute
for Life Science for Laboratory Animal Care and Use (Seoul, Korea), where the animals
had free access to water and food, and were housed on 12h light/12 h dark cycle.
Compound treatment to animals. Chemicals used were freshly prepared
shortly before administration to the animals. We treated 5FAD mice with 1
(1mg kg 1 of body weight) or the vehicle (1% v/v DMSO in 20mM HEPES, pH
7.4, 150mM NaCl) starting at 3 months of age, which is the same method used in
our previous studies25,29. 1 was daily injected into the lower abdomen of the
5FAD mice for 30 days.
Assessment of cognitive function by the Morris water maze test. Mice were
subjected to the Morris water maze test to assess their performance of spatial
learning and memory25,61. The water maze was a circular plastic pool (120 cm
diameter) and ﬁlled with murky water (21.0±1.0 C). A cylindrical escape platform
(15 cm diameter) stood 0.5 cm under the water surface. Three hours after the 30th
compound treatment, the mice were allowed the ﬁrst training to swim and ﬁnd the
hidden escape platform in the water with three repeats per training. Thereafter,
they daily tried the task on the next 4 consecutive days. Three hours after the ﬁnal
escape test, the platform was removed, and the mice exercised a probe trial for 60 s.
The animal performance was traced with SMART Video Tracking System
(Harvard Apparatus, Holliston, MA, USA).
Tissue preparation. Immediately after the behavioural test, the mice were sacri-
ﬁced under deep anaesthesia. The brain was divided into left and right cerebral
hemispheres for biochemical and histological analysis, respectively and quickly
frozen in liquid nitrogen.
ELISA for quantiﬁcation of the cerebral Ab. We measured the levels of various
types of Ab in the brain as described previously25,29. The protein fractions were
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serially prepared from the left hemispheres in PBS (pH 7.4), in 2% SDS and in 70%
FA, and then subjected to the human Ab40 and Ab42 ELISA quantiﬁcation
according to the manufacturer’s methods (Invitrogen, Carlsbad, CA, USA). The
aggregated (Invitorgen) and oligomeric Ab (82E1-speciﬁc; IBL International,
Hamburg, Germany) ELISA quantiﬁcations were also performed using PBS
fractions. The cerebral levels of Ab40 and Ab42 were represented as moles per gram
of wet brain tissue, whereas the aggregated or oligomeric Ab amounts were
expressed as grams per gram of wet brain tissue.
Histological quantiﬁcation of cerebral amyloid pathology. 12-mm sagittal
sections of the brain were prepared from the right hemispheres on a cryostat
(HM550; Microm, Walldorf, Germany), and mounted onto 1% poly-L-lysine-
coated glass slides. Immunohistochemistry was performed on the tissue section
using the human Ab(17–24)-speciﬁc antibody 4G8 (Covance, Princeton, NJ, USA).
They were immunologically reacted with 4G8 (1:1,000 dilution) and biotinylated
anti-mouse IgG secondary antibody (Vector Laboratories, Burlingame, CA, USA),
and then developed with 0.015% diaminobenzidine/0.001% H2O2 (in PBS; Vector
Laboratories). The immuno-reacted sections were examined or photographed
under a light microscope (Eclipse 80i; Nikon, Tokyo, Japan). The congophillic
amyloid plaques were examined after staining the sections with Accustain Congo
Red amyloid staining solution (Sigma). The loads of amyloid deposits in the brain
were expressed as the per cent area of 4G8-immunoreactive deposits or the number
of congophilic plaques per mm2 of a cortical region of interest.
Statistics. Data are expressed as mean±s.e.m. Statistical differences between
groups were determined with the unpaired t-test. Statistical signiﬁcance was
considered at Po0.05. The current animal study was performed in parallel with the
study previously reported29 using the same control groups (vehicle-treated
wild-type and 5FAD mice); thus, the same control data were used in both studies.
Data availability. All relevant data are available from the authors upon request.
References
1. Beck, M. W., Pithadia, A. S., DeToma, A. S., Korshavn, K. J. & Lim, M. H. in
Ligand Design in Medicinal Inorganic Chemistry. Ch. 10 (Wiley, Chichester,
2014).
2. Derrick, J. S. & Lim, M. H. Tools of the trade: Investigations into design
strategies of small molecules to target componets in Alzheimer’s disease.
ChemBioChem 16, 887–898 (2015).
3. Jakob-Roetne, R. & Jacobsen, H. Alzheimer’s disease: from pathology to
therapeutic approaches. Angew Chem. Int. Ed. Engl. 48, 3030–3059 (2009).
4. Bush, A. I. et al. Rapid induction of Alzheimer Ab amyloid formation by zinc.
Science 265, 1464–1467 (1994).
5. Soto, C. Unfolding the role of protein misfolding in neurodegenerative diseases.
Nat. Rev. Neurosci. 4, 49–60 (2003).
6. Savelieff, M. G., Lee, S., Liu, Y. & Lim, M. H. Untangling amyloid-b, tau, and
metals in Alzheimer’s disease. ACS Chem. Biol. 8, 856–865 (2013).
7. Greenough, M. A., Camakaris, J. & Bush, A. I. Metal dyshomeostasis and
oxidative stress in Alzheimer’s disease. Neurochem. Int. 62, 540–555 (2013).
8. Ayton, S., Lei, P. & Bush, A. I. Biometals and their therapeutic implications in
Alzheimer’s disease. Neurotherapeutics 12, 109–120 (2015).
9. Barnham, K. J. & Bush, A. I. Biological metals and metal-targeting compounds
in major neurodegenerative diseases. Chem. Soc. Rev. 43, 6727–6749 (2014).
10. Barnham, K. J., Masters, C. L. & Bush, A. I. Neurodegenerative diseases and
oxidative stress. Nat. Rev. Drug Discov. 3, 205–214 (2004).
11. Ayton, S., Lei, P. & Bush, A. I. Metallostasis in Alzheimer’s disease. Free. Radic.
Biol. Med. 62, 76–89 (2013).
12. Rowinska-Zyrek, M., Salerno, M. & Kozlowski, H. Neurodegenerative
diseases—Understanding their molecular bases and progress in the
development of potential treatments. Coord. Chem. Rev. 284, 298–312 (2015).
13. DeToma, A. S., Salamekh, S., Ramamoorthy, A. & Lim, M. H. Misfolded
proteins in Alzheimer’s disease and type II diabetes. Chem. Soc. Rev. 41,
608–621 (2012).
14. Leal, S. S., Botelho, H. M. & Gomes, C. M. Metal ions as modulators of protein
conformation and misfolding in neurodegeneration. Coord. Chem. Rev. 256,
2253–2270 (2012).
15. Viles, J. H. Metal ions and amyloid ﬁber formation in neurodegenerative
diseases. Copper, zinc and iron in Alzheimer’s, Parkinson’s and prion diseases.
Coord. Chem. Rev. 256, 2271–2284 (2012).
16. Kepp, K. P. Bioinorganic chemistry of Alzheimer’s disease. Chem. Rev. 112,
5193–5239 (2012).
17. Faller, P. & Hureau, C. A bioinorganic view of Alzheimer’s disease: when
misplaced metal ions (re)direct the electrons to the wrong target. Eur. J. Chem
18, 15910–15920 (2012).
18. Faller, P., Hureau, C. & La Penna, G. Metal ions and intrinsically disordered
proteins and peptides: from Cu/Zn amyloid-b to general principles. Acc. Chem.
Res. 47, 2252–2259 (2014).
19. Que, E. L., Domaille, D. W. & Chang, C. J. Metals in neurobiology: probing
their chemistry and biology with molecular imaging. Chem. Rev. 108,
1517–1549 (2008).
20. Rodrı´guez-Rodrı´guez, C., Telpoukhovskaia, M. & Orvig, C. The art of building
multifunctional metal-binding agents from basic molecular scaffolds for the
potential application in neurodegenerative diseases. Coord. Chem. Rev. 256,
2308–2332 (2012).
21. Perez, L. R. & Franz, K. J. Minding metals: tailoring multifunctional
chelating agents for neurodegenerative disease. Dalton Trans. 39, 2177–2187
(2010).
22. Savelieff, M. G., DeToma, A. S., Derrick, J. S. & Lim, M. H. The ongoing search
for small molecules to study metal-associated amyloid-b species in Alzheimer’s
disease. Acc. Chem. Res. 47, 2475–2482 (2014).
23. Telpoukhovskaia, M. A. & Orvig, C. Werner coordination chemistry and
neurodegeneration. Chem. Soc. Rev. 42, 1836–1846 (2013).
24. Choi, J.-S., Braymer, J. J., Nanga, R. P. R., Ramamoorthy, A. & Lim, M. H.
Design of small molecules that target metal–Ab species and regulate
metal-induced Ab aggregation and neurotoxicity. Proc. Natl Acad. Sci. USA
107, 21990–21995 (2010).
25. Beck, M. W. et al. A rationally designed small molecule for identifying an
in vivo link between metal-amyloid-b complexes and the pathogenesis of
Alzheimer’s disease. Chem. Sci 6, 1879–1886 (2015).
26. Kerns, E. H. & Di, L. in Drug-like Properties: Concepts, Structure Design and
Methods. Ch. 8 (Academic Press, 2008).
27. Hyung, S. J. et al. Insights into antiamyloidogenic properties of the green tea
extract ( )-epigallocatechin-3-gallate toward metal-associated amyloid-b
species. Proc. Natl Acad. Sci. USA 110, 3743–3748 (2013).
28. Lee, S. et al. Rational design of a structural framework with potential use to
develop chemical reagents that target and modulate multiple facets of
Alzheimer’s disease. J. Am. Chem. Soc. 136, 299–310 (2014).
29. Derrick, J. S. et al. A redox-active, compact tool for crosslinking amyloidogenic
peptides into off-pathway aggregates: in vitro and in vivo efﬁcacy and molecular
mechanisms. J. Am. Chem. Soc. 137, 14785–14797 (2015).
30. Charkoudian, L. K., Pham, D. M. & Franz, K. J. A pro-chelator triggered by
hydrogen peroxide inhibits iron-promoted hydroxyl radical formation. J. Am.
Chem. Soc. 128, 12424–12425 (2006).
31. Cherny, R. A. et al. Treatment with a copper-zinc chelator markedly and
rapidly inhibits b-amyloid accumulation in Alzheimer’s disease transgenic
mice. Neuron 30, 665–676 (2001).
32. Adlard, P. A. et al. Rapid restoration of cognition in Alzheimer’s transgenic
mice with 8-hydroxy quinoline analogs is associated with decreased interstitial
Ab. Neuron 59, 43–55 (2008).
33. Potts, H. A. & Smith, G. F. The structure of pyrrole trimer. J. Chem. Soc.
4018–4022 (1957).
34. Tan, Y. & Ghandi, K. Kinetics and mechanism of pyrrole chemical
polymerization. Synth. Met. 175, 183–191 (2013).
35. Michaelis, L., Schubert, M. P. & Granick, S. The free radicals of the type of
Wurster’s salts. J. Am. Chem. Soc. 61, 1981–1992 (1939).
36. Maleki, A. & Nematollahi, D. Mechanism diversity in anodic oxidation of
N,N-dimethyl-p-phenylenediamine by varying pH. J. Electroanal. Chem. 704,
75–79 (2013).
37. Modestov, A. D., Gun, J., Savotine, I. & Lev, O. On-line electrochemical–mass
spectrometry study of the mechanism of oxidation of N,N-dimethyl-p-
phenylenediamine in aqueous electrolytes. J. Electroanal. Chem. 565, 7–19
(2004).
38. Nickel, U., Peris, C. V. & Ramminger, U. A radical chain mechanism coupled to
autocatalysis. The oxidation of N,N-dimethyl-p-phenylenediamine by
peroxodisulfate. J. Phys. Chem. A 106, 3773–3786 (2002).
39. Hureau, C. & Dorlet, P. Coordination of redox active metal ions to the amyloid
precursor protein and to amyloid-b peptides involved in Alzheimer disease.
Part 2: dependence of Cu(II) binding sites with Ab sequences. Coord. Chem.
Rev. 256, 2175–2187 (2012).
40. Hernandez, H. & Robinson, C. V. Determining the stoichiometry and
interactions of macromolecular assemblies from mass spectrometry. Nat.
Protoc. 2, 715–726 (2007).
41. Hilton, G. R. & Benesch, J. L. Two decades of studying non-covalent
biomolecular assemblies by means of electrospray ionization mass
spectrometry. J. R. Soc. Interface 9, 801–816 (2012).
42. Lanucara, F., Holman, S. W., Gray, C. J. & Eyers, C. E. The power of ion
mobility-mass spectrometry for structural characterization and the study of
conformational dynamics. Nat. Chem. 6, 281–294 (2014).
43. Stadtman, E. R. & Levine, R. L. Protein oxidation. Ann. N. Y. Acad. Sci. 899,
191–208 (2000).
44. Scho¨neich, C. & Williams, T. D. Cu(II)-catalyzed oxidation of b-amyloid
peptide targets His13 and His14 over His6: detection of 2-oxo-histidine by
HPLC-MS/MS. Chem. Res. Toxicol. 15, 717–722 (2002).
45. Uchida, K. Histidine and lysine as targets of oxidative modiﬁcation. Amino
Acids 25, 249–257 (2003).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13115
12 NATURE COMMUNICATIONS | 7:13115 | DOI: 10.1038/ncomms13115 | www.nature.com/naturecommunications
46. Hawkins, C. L. & Davies, M. J. Generation and propagation of radical reactions
on proteins. Biochim. Biophys. Acta 1504, 196–219 (2001).
47. Garrison, W. M. Reaction mechanisms in the radiolysis of peptides,
polypeptides, and proteins. Chem. Rev. 87, 381–398 (1987).
48. Porter, M. R., Kochi, A., Karty, J. A., Lim, M. H. & Zaleski, J. M. Chelation-
induced diradical formation as an approach to modulation of the amyloid-b
aggregation pathway. Chem. Sci. 6, 1018–1026 (2015).
49. Halliwell, B. Antioxidants: the basics-what they are and how to evaluate them.
Adv. Pharmacol. 38, 3–20 (1996).
50. Di, L., Kerns, E. H., Fan, K., McConnell, O. J. & Carter, G. T. High throughput
artiﬁcial membrane permeability assay for blood-brain barrier. Eur. J. Med.
Chem. 38, 223–232 (2003).
51. Avdeef, A. et al. PAMPA-critical factors for better predictions of absorption.
J. Pharm. Sci. 96, 2893–2909 (2007).
52. BBB protocol and test compounds; pION, Inc. Woburn, MA (2009).
53. Mruk, D. D. & Cheng, C. Y. Enhanced chemiluminescence (ECL) for routine
immunoblotting: an inexpensive alternative to commercially available kits.
Spermatogenesis 1, 121–122 (2011).
54. Spencer, V. A., Sun, J. M., Li, L. & Davie, J. R. Chromatin immunoprecipitation:
a tool for studying histone acetylation and transcription factor binding.
Methods 31, 67–75 (2003).
55. Braymer, J. J. et al. Development of bifunctional stilbene derivatives for targeting
and modulating metal-amyloid-b species. Inorg. Chem. 50, 10724–10734 (2011).
56. Gans, P., Sabatini, A. & Vacca, A. Determination of equilibrium constants from
spectrophotometric data obtained from solutions of known pH: the program
pHab. Ann. Chim. 89, 45–49 (1999).
57. Alderighi, L. et al. Hyperquad simulation and speciation (HySS): a utility
program for the investigation of equilibria involving soluble and partially
soluble species. Coord. Chem. Rev. 184, 311–318 (1999).
58. Ruotolo, B. T., Benesch, J. L. P., Sandercock, A. M., Hyung, S.-J. & Robinson, C. V.
Ion mobility–mass spectrometry analysis of large protein complexes. Nat. Protoc.
3, 1139–1152 (2008).
59. Bush, M. F. et al. Collision cross sections of proteins and their complexes: a
calibration framework and database for gas-phase structural biology. Anal.
Chem. 82, 9557–9565 (2010).
60. Frisch, M. J. et al. Gaussian, Inc., Gaussian 09, Revision A.02 (Gaussian, Inc.,
Wallingford CT, USA, 2009.
61. Oakley, H. et al. Intraneuronal b-amyloid aggregates, neurodegeneration, and
neuron loss in transgenic mice with ﬁve familial Alzheimer’s disease mutations:
potential factors in amyloid plaque formation. J. Neurosci. 26, 10129–10140 (2006).
Acknowledgements
This work was supported by the 2016 Research Fund (Project Number 1.160001.01)
of Ulsan National Institute of Science and Technology (UNIST) and the National
Research Foundation of Korea (NRF) grant funded by the Korean government
(NRF-2014R1A2A2A01004877 and NRF-2014S1A2A2028270) (to M.H.L.); the Uni-
versity of Michigan Protein Folding Disease Initiative (to B.T.R. and M.H.L.); the Asan
Institute for Life Sciences, Asan Medical Center (2015-7012) and the National Research
Foundation of Korea (NRF) grant funded by the Korean government (NRF-
2015R1A2A1A15052049) (to J.-Y.L.); National Honor Scientist Program (2010-0020414)
of National Research Foundation of Korea (to K.S.K.). We thank Akiko Kochi, Han
Myung Lee, Younwoo Nam and Milim Jang for their assistance with PAMPA and
deoxyribose assays, calculation studies, TEM measurements and TEAC/MTT assays,
respectively.
Author contributions
M.H.L., M.W.B. and J.S.D. designed research. M.W.B., J.S.D., Y.J., J.H., S.D.L. and M.H.L.
contributed new reagents. M.W.B., J.S.D., Y.J. and J.H. were fully or partially involved in
acquiring and analysing the data from gel/western, TEM, solution studies (speciation,
metal binding and stability; UV–vis and ESI–MS), in vitro assays of PAMPA-BBB, TEAC
and deoxyribose and cell studies (MTT assay). R.A.K. and B.T.R. carried out the studies of
compounds’ interactions with metal-free and Cu(II)-treated Ab by mass spectrometry
(nESI-MS and IM–MS) and analysed the data. S.B.O., N.S., S.K. and J.-Y.L. conducted
in vivo studies with the data analysis. W.J.C., Z.A.T. and K.S.K. performed computational
studies with the data analysis. S.J.C.L. obtained and analysed MS data for compounds’
reactivities with metal-free Ab and Cu(II)–Ab by MALDI–MS and ESI–MS. M.H.L., J.S.D.
and M.W.B. wrote the paper with input from all authors.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Beck, M. W. et al. Structure-mechanism-based engineering
of chemical regulators targeting distinct pathological factors in Alzheimer’s disease.
Nat. Commun. 7, 13115 doi: 10.1038/ncomms13115 (2016).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) 2016
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13115 ARTICLE
NATURE COMMUNICATIONS | 7:13115 | DOI: 10.1038/ncomms13115 | www.nature.com/naturecommunications 13
